MiPLA: Difference between revisions

Line 130:

{{#ask: [[Category:MiPLA]][[Category:Experience]]|format=ul|Columns=1}}

Additional experience reports can be found here:

* [https://~~www.~~erowid.org/experiences/subs/~~exp_ALLAD~~.shtml Erowid Experience Vaults: MiPLA]

* [https://erowid.org/experiences/subs/exp_MIPLA.shtml Erowid Experience Vaults: MiPLA]

==Toxicity and harm potential==

Line 144:

It is strongly recommended that one uses [[responsible drug use|harm reduction practices]] when using this substance.

===~~Tolerance~~ and ~~addiction~~ potential===

===Dependence and abuse potential===

Although no formal studies have been conducted, it is not unreasonable to assume that as with LSD itself, MiPLA is [[Addiction potential::not habit-forming]] and that the desire to use it can actually decrease with use.

Line 152:

===Overdose===

The LD<sub>50</sub> of MiPLA is unknown. Adverse psychological reactions may be ~~become~~ more likely to occur at higher doses. Some of these include [[anxiety]], [[delusions]], [[panic attacks]] and more rarely [[seizures]]. Medical attention is usually only needed if suspected of severe psychotic episodes or “fake acid” (such as [[25i-NBOMe]] or [[DOB]]). Administration of [[benzodiazepines]] or [[antipsychotics]] can help to relieve the negative cognitive effects of MiPLA.

The LD<sub>50</sub> of MiPLA is unknown. Adverse psychological reactions may be more likely to occur at higher doses. Some of these include [[anxiety]], [[delusions]], [[panic attacks]] and more rarely [[seizures]]. Medical attention is usually only needed if suspected of severe psychotic episodes or “fake acid” (such as [[25i-NBOMe]] or [[DOB]]). Administration of [[benzodiazepines]] or [[antipsychotics]] can help to relieve the negative cognitive effects of MiPLA.

===Dangerous interactions===

Line 160:

*'''[[Stimulants]]''' - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable [[anxiety]], [[Panic attacks|panic]], [[thought loops]] and [[paranoia]]. This interaction may cause elevated risk of psychosis.{{citation needed}}

*'''[https://en.wikipedia.org/wiki/Lithium_(medication) Lithium]''' - Lithium is often used as treatment for bipolar disorder. It may possibly cause elevated risk of seizures and psychosis due to its [[Glutamate|glutaminergic]] and [[GABA|GABAergic]] effects.{{citation needed}}

==Legal status==

MiPLA is currently a gray area compound within most parts of the world. This means that it is not known to be specifically illegal within most countries, but people may still be charged for its possession under certain circumstances such as under analog laws and with the intent to sell or consume.

*'''Austria:''' MiPLA is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD. {{citation needed}}

*'''United States:''' MiPLA is unscheduled but can be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the Federal Analogue Act.

==See also==

*[[Responsible use]]

*[[Research chemical]]

*[[Psychedelics]]

*[[Lysergamides]]

*[[LSZ]]

*[[LSD]]

==External links==

* [https://en.wikipedia.org/wiki/Methylisopropyllysergamide MiPLA (Wikipedia)]

* [https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5327 MiPLA (TiHKAL / Isomer Design)]

===Discussion===

* [http://www.bluelight.org/vb/threads/784440-The-Small-amp-Handy-MIPLA-(Methylisopropyllysergamide)-Thread The Small & Handy MiPLA Thread (Bluelight)]

==Literature==

* Halberstadt, A. L., Klein, L. M., Chatha, M., Valenzuela, L. B., Stratford, A., Wallach, J., ... & Brandt, S. D. (2018). Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA). Psychopharmacology, 1-10. http://dx.doi.org/10.1007/s00213-018-5055-9

~~==Further reading==~~

* [https://heffter.org/docs/hrireview/02/chap6.pdf Nichols, D. E. (2001). LSD and its lysergamide cousins. The Heffter Review of Psychedelic Research. Santa Fe, New Mexico: Heffter Research Institute, 80-87.]

==References==

@@ Line 130: / Line 130: @@
 {{#ask: [[Category:MiPLA]][[Category:Experience]]|format=ul|Columns=1}}
 Additional experience reports can be found here:
-* [https://www.erowid.org/experiences/subs/exp_ALLAD.shtml Erowid Experience Vaults: MiPLA]
+* [https://erowid.org/experiences/subs/exp_MIPLA.shtml Erowid Experience Vaults: MiPLA]
 ==Toxicity and harm potential==
@@ Line 144: / Line 144: @@
 It is strongly recommended that one uses [[responsible drug use|harm reduction practices]] when using this substance.
-===Tolerance and addiction potential===
+===Dependence and abuse potential===
 Although no formal studies have been conducted, it is not unreasonable to assume that as with LSD itself, MiPLA is [[Addiction potential::not habit-forming]] and that the desire to use it can actually decrease with use.
@@ Line 152: / Line 152: @@
 ===Overdose===
-The LD<sub>50</sub> of MiPLA is unknown. Adverse psychological reactions may be become more likely to occur at higher doses. Some of these include [[anxiety]], [[delusions]], [[panic attacks]] and more rarely [[seizures]]. Medical attention is usually only needed if suspected of severe psychotic episodes or “fake acid” (such as [[25i-NBOMe]] or [[DOB]]). Administration of [[benzodiazepines]] or [[antipsychotics]] can help to relieve the negative cognitive effects of MiPLA.
+The LD<sub>50</sub> of MiPLA is unknown. Adverse psychological reactions may be more likely to occur at higher doses. Some of these include [[anxiety]], [[delusions]], [[panic attacks]] and more rarely [[seizures]]. Medical attention is usually only needed if suspected of severe psychotic episodes or “fake acid” (such as [[25i-NBOMe]] or [[DOB]]). Administration of [[benzodiazepines]] or [[antipsychotics]] can help to relieve the negative cognitive effects of MiPLA.
 ===Dangerous interactions===
@@ Line 160: / Line 160: @@
 *'''[[Stimulants]]''' - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable [[anxiety]], [[Panic attacks|panic]], [[thought loops]] and [[paranoia]]. This interaction may cause elevated risk of psychosis.{{citation needed}}
 *'''[https://en.wikipedia.org/wiki/Lithium_(medication) Lithium]''' - Lithium is often used as treatment for bipolar disorder. It may possibly cause elevated risk of seizures and psychosis due to its [[Glutamate|glutaminergic]] and [[GABA|GABAergic]] effects.{{citation needed}}
+==Legal status==
+{{legalStub}}
+MiPLA is currently a gray area compound within most parts of the world. This means that it is not known to be specifically illegal within most countries, but people may still be charged for its possession under certain circumstances such as under analog laws and with the intent to sell or consume.
+*'''Austria:''' MiPLA is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD. {{citation needed}}
+*'''United States:''' MiPLA is unscheduled but can be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the Federal Analogue Act.
+==See also==
+*[[Responsible use]]
+*[[Research chemical]]
+*[[Psychedelics]]
+*[[Lysergamides]]
+*[[LSZ]]
+*[[LSD]]
+==External links==
+* [https://en.wikipedia.org/wiki/Methylisopropyllysergamide MiPLA (Wikipedia)]
+* [https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5327 MiPLA (TiHKAL / Isomer Design)]
+===Discussion===
+* [http://www.bluelight.org/vb/threads/784440-The-Small-amp-Handy-MIPLA-(Methylisopropyllysergamide)-Thread The Small & Handy MiPLA Thread (Bluelight)]
 ==Literature==
 * Halberstadt, A. L., Klein, L. M., Chatha, M., Valenzuela, L. B., Stratford, A., Wallach, J., ... & Brandt, S. D. (2018). Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA). Psychopharmacology, 1-10. http://dx.doi.org/10.1007/s00213-018-5055-9
-==Further reading==
 * [https://heffter.org/docs/hrireview/02/chap6.pdf Nichols, D. E. (2001). LSD and its lysergamide cousins. The Heffter Review of Psychedelic Research. Santa Fe, New Mexico: Heffter Research Institute, 80-87.]
 ==References==
 <references />